ArticleOphthalmology. Retina2022
Age, Gender, and Laterality of Retinal Vascular Occlusion: A Retrospective Study from the IRIS® Registry.
Article in Ophthalmology. Retina, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Exploring the role of oxidative stress in retinal vein occlusion: an updated and comprehensive review on the pathophysiology and treatment perspectives.International ophthalmology · 2025Pooled it
- Age-independent anti-angiogenic therapy for choroidal neovascularization by targeting secretogranin III.GeroScience · 2026Article
- Optimal Treatment of Retinal Vein Occlusion: An Updated Canadian Review and Recommendations.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Central Retinal Artery Occlusion in Acute Care: Current Practices and Emerging Therapies.Cureus · 2025Review
- Branch Retinal Artery Occlusion in a Young Adult: A Diagnostic Clue to Systemic Embolic Risk.Cureus · 2025Article
- Predicting Visual Acuity after Retinal Vein Occlusion Anti-VEGF Treatment: Development and Validation of an Interpretable Machine Learning Model.Journal of medical systems · 2025Article
- Catalytic neural stem cell exosomes for multi-stage targeting and synergistical therapy of retinal ischemia-reperfusion injury.Cell reports. Medicine · 2025Article
- Atrial fibrillation in Retinal Artery Occlusions.Cardiology and cardiovascular medicine · 2025Article
- Relationship Between COVID-19 and Retinal Vein Occlusions.Journal of ophthalmology · 2025Review
- Utility of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in individuals with retinal vein occlusion.Frontiers in cardiovascular medicine · 2025Article
- Branch Retinal Artery Occlusion as a Presentation of Seronegative Antiphospholipid Syndrome in Pregnancy.Cureus · 2024Article
- Optimizing open-angle glaucoma risk assessment in patients with retinal vein occlusions.Eye (London, England) · 2024Article
- Vitamin D deficiency in patients with retinal vein occlusion: a systematic review and meta-analysis.International journal of retina and vitreous · 2024Review
- Incidence rates of retinal vascular occlusive diseases from 2011 to 2020 in South Korea: a nationwide cohort study.BMC ophthalmology · 2024Article
- Impact of high-risk optic disc on central retinal vein occlusion in patients with metabolic disorders.Frontiers in physiology · 2024Article
- Sodium-glucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study.Scientific reports · 2023Article
- Description of a Nonhuman Primate Model of Retinal Ischemia/Reperfusion Injury.Translational vision science & technology · 2023Article
- Prevalence and risk factors of retinal vein occlusion in the United States: The National Health and Nutrition Examination Survey, 2005 to 2008.Proceedings (Baylor University. Medical Center) · 2023Article
- Central retinal vein occlusion in young population: risk factors and outcomes.Frontiers in medicine · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
purposeRetinal vascular occlusion is a leading cause of profound irreversible visual loss, but the understanding of the disease is insufficient. We systematically investigated the age, gender, and laterality at the onset of retinal artery occlusion (RAO) and retinal vein occlusion (RVO) in the Intelligent Research in Sight (IRIS®) Registry.
designRetrospective registry cohort.
participantsPatients with retinal vascular occlusion participating in the IRIS® Registry.
methodsPatients who received a diagnosis of retinal vascular occlusion between 2013 and 2017 were included. Those with unspecified gender or laterality were excluded when conducting the relevant analyses. Patients were categorized into RAO, with subtypes transient retinal artery occlusion (TRAO), partial retinal artery occlusion (PRAO), branch retinal artery occlusion (BRAO), and central retinal artery occlusion (CRAO), and into RVO, with subtypes venous engorgement (VE), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). Age was evaluated as a categorical variable (5-year increments). We investigated the association of age, gender, and laterality with the onset frequency of retinal vascular occlusion subtypes.
main outcome measuresThe frequency of onset of RAO and RVO subtypes by age, gender and laterality.
resultsA total of 1 251 476 patients with retinal vascular occlusion were included, 23.8% of whom had RAO, whereas 76.2% had RVO. Of these, 1 248 656 and 798 089 patients were selected for analyses relevant to gender and laterality, respectively. The onset frequency of all subtypes increased with age. PRAO, BRAO, CRAO, and CRVO presented more frequently in men (53.5%, 51.3%, 52.6%, and 50.4%, respectively), whereas TRAO, VE, and BRVO presented more frequently in women (54.9%, 56.0%, and 54.5% respectively). All RAO subtypes and BRVO showed a right-eye onset preference (TRAO, 51.7%; PRAO, 54.4%; BRAO, 53.5%; CRAO, 53.4%; and BRVO, 51.0%), whereas VE and CRVO exhibited a left-eye onset preference (53.3% and 50.9%, respectively).
conclusionsAlthough retinal vascular occlusion incidence increases with age regardless of subtypes, we found various subtype-specific disease-onset differences related to gender and, in particular, ocular laterality. These findings may improve understanding of the specific cause of retinal vascular occlusions of different subtypes and their relationships with structural and anatomic asymmetries of the vascular system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.